NEW YORK, March 6 (GenomeWeb News) - Johnson & Johnson's decision to downsize its R&D program, disclosed last month, will not affect existing alliances, including genomic-related partnerships, the company said Friday.
Company spokesperson Ernie Knewitz told GenomeWeb News last week that existing research deals were still under way, but could not comment on the future of the division's budget for such alliances.
Knewitz also said that "not many" of the 300 positions eliminated were in genomics research. "The majority of the genomics work is being done in La Jolla [California] and in Pennsylvania."
The lay-offs are in the company's Raritan, NJ office.
Laid-off employees will be able to apply for 100 new positions in the Spring House, Pa., office.
Companies GenomeWeb News spoke to who have collaborated with J&JPRD recently said they were not affected by the lay-offs.
"J&J is still one of our greatest partners. We're still very gung-ho here," said Jill Fujisaki, vice president scientific alliances of Entelos, which recently expanded a hematology research collaboration with the company.
Another company, GeneGo, renewed its database license to J&JPRD two weeks ago. GeneGo said the deal was for 12 months and represents the third year of that relationship.